Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

Implant Dentistry of Greater Lansing ( is excited to unveil its new website to the public. The improved website allows ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novonesis is a strong business with stable margins and high ROIC, but recent growth rates have declined. See why NVZMF stock ...

Teenagers may be less likely to initiate tobacco smoking if they engage in moderate-to-vigorous physical activity (MVPA) from ...

In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...

The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for the project. The NNF – a ...

UK pharmacies regulator tightens rules on prescribing obesity drugs 12:11 AM UTC The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.